{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:00:16Z","timestamp":1781056816083,"version":"3.54.1"},"publisher-location":"Cham","reference-count":177,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032003805","type":"print"},{"value":"9783032003812","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/5584_2025_863","type":"book-chapter","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T04:35:46Z","timestamp":1745555746000},"page":"161-183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination Therapies in Drug Repurposing: Personalized Approaches to Combatting Leukaemia and Multiple Myeloma"],"prefix":"10.1007","author":[{"given":"B.","family":"Monchusi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Takundwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. L.","family":"Kenmogne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Malise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. B.","family":"Thimiri Govinda Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"issue":"4","key":"863_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41587-022-01269-3","volume":"40","author":"M Aboy","year":"2022","unstructured":"Aboy M, Liddell K, Jordan M, Crespo C, Liddicoat J (2022) European patent protection for medical uses of known products and drug repurposing. Nat Biotechnol 40(4):465\u2013471","journal-title":"Nat Biotechnol"},{"issue":"12","key":"863_CR2","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1016\/j.clml.2020.07.003","volume":"20","author":"A Afzal","year":"2020","unstructured":"Afzal A, Fiala MA, Gage BF, Wildes TM, Sanfilippo K (2020) Statins reduce mortality in multiple myeloma: a population-based US study. Clin Lymphoma Myeloma Leuk 20(12):e937\u2013e943","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"863_CR3","doi-asserted-by":"publisher","first-page":"13398","DOI":"10.1038\/s41598-023-40160-2","volume":"13","author":"PC Agu","year":"2023","unstructured":"Agu PC, Afiukwa CA, Orji OU, Ezeh EM, Ofoke IH, Ogbu CO et al (2023) Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep 13(1):13398","journal-title":"Sci Rep"},{"issue":"4","key":"863_CR4","doi-asserted-by":"publisher","first-page":"103936","DOI":"10.1016\/j.drudis.2024.103936","volume":"29","author":"SE Alavi","year":"2024","unstructured":"Alavi SE, Alharthi S, Alavi SF, Alavi SZ, Zahra GE, Raza A et al (2024) Microfluidics for personalized drug delivery. Drug Discov Today 29(4):103936","journal-title":"Drug Discov Today"},{"issue":"2","key":"863_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3109\/10428194.2013.793323","volume":"55","author":"OS Aljitawi","year":"2014","unstructured":"Aljitawi OS, Li D, Xiao Y, Zhang D, Ramachandran K, Stehno-Bittel L et al (2014) A novel three-dimensional stromal-based model for in vitro chemotherapy sensitivity testing of leukemia cells. Leuk Lymphoma 55(2):378\u2013391","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"863_CR6","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.3390\/cancers16132381","volume":"16","author":"OS Al-Odat","year":"2024","unstructured":"Al-Odat OS, Nelson E, Budak-Alpdogan T, Jonnalagadda SC, Desai D, Pandey MK (2024) Discovering potential in non-cancer medications: a promising breakthrough for multiple myeloma patients. Cancers 16(13):2381","journal-title":"Cancers"},{"issue":"5","key":"863_CR7","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.clml.2024.01.002","volume":"24","author":"I Alodhaibi","year":"2024","unstructured":"Alodhaibi I, Ailawadhi S, Burbano GP, O\u2019Brien PJ, Buadi FK, Hayman S et al (2024) An open-label phase I study of metformin and nelfinavir in combination with bortezomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 24(5):298\u2013304","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"863_CR8","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/molecules28031210","volume":"28","author":"R Alves","year":"2023","unstructured":"Alves R, Santos D, Jorge J, Gon\u00e7alves AC, Catarino S, Gir\u00e3o H et al (2023) Alvespimycin inhibits heat shock protein 90 and overcomes imatinib resistance in chronic myeloid leukemia cell lines. Molecules 28(3):1210","journal-title":"Molecules"},{"issue":"7","key":"863_CR9","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/s41564-023-01377-z","volume":"8","author":"A Amambua-Ngwa","year":"2023","unstructured":"Amambua-Ngwa A, Button-Simons KA, Li X, Kumar S, Brenneman KV, Ferrari M et al (2023) Chloroquine resistance evolution in Plasmodium falciparum is mediated by the putative amino acid transporter AAT1. Nat Microbiol 8(7):1213\u20131226","journal-title":"Nat Microbiol"},{"issue":"3","key":"863_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3324\/haematol.2019.240754","volume":"106","author":"AJ Ambinder","year":"2020","unstructured":"Ambinder AJ, Levis M (2020) Potential targeting of FLT3 acute myeloid leukemia. Haematologica 106(3):671","journal-title":"Haematologica"},{"issue":"3","key":"863_CR11","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.3390\/molecules28031438","volume":"28","author":"FA Ambrosio","year":"2023","unstructured":"Ambrosio FA, Costa G, Gallo Cantafio ME, Torcasio R, Trapasso F, Alcaro S et al (2023) Natural agents as novel potential source of proteasome inhibitors with anti-tumor activity: focus on multiple myeloma. Molecules 28(3):1438","journal-title":"Molecules"},{"issue":"1","key":"863_CR12","doi-asserted-by":"publisher","first-page":"vbad143","DOI":"10.1093\/bioadv\/vbad143","volume":"3","author":"L Aswad","year":"2023","unstructured":"Aswad L, Jafari R (2023) FORALL: an interactive shiny\/R web portal to navigate multi-omics high-throughput data of pediatric acute lymphoblastic leukemia. Bioinform Adv 3(1):vbad143","journal-title":"Bioinform Adv"},{"issue":"18","key":"863_CR13","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.3390\/cancers13184557","volume":"13","author":"D Avsec","year":"2021","unstructured":"Avsec D, Jako\u0161 Djordjevi\u010d AT, Kandu\u0161er M, Podgornik H, \u0160kerget M, Mlinari\u010d-Ra\u0161\u010dan I (2021) Targeting autophagy triggers apoptosis and complements the action of venetoclax in chronic lymphocytic leukemia cells. Cancers 13(18):4557","journal-title":"Cancers"},{"issue":"2","key":"863_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/1535-7163.MCT-08-0664","volume":"8","author":"P Baumann","year":"2009","unstructured":"Baumann P, Mandl-Weber S, V\u00f6lkl A, Adam C, Bumeder I, Oduncu F et al (2009) Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 8(2):366\u2013375","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"863_CR15","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/leu.2014.27","volume":"28","author":"J Berenson","year":"2014","unstructured":"Berenson J, Hilger J, Yellin O, Dichmann R, Patel-Donnelly D, Boccia RV et al (2014) Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy. Leukemia 28(7):1529\u20131536","journal-title":"Leukemia"},{"issue":"12","key":"863_CR16","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","volume":"12","author":"F Bertolini","year":"2015","unstructured":"Bertolini F, Sukhatme VP, Bouche G (2015) Drug repurposing in oncology\u2014patient and health systems opportunities. Nat Rev Clin Oncol 12(12):732\u2013742","journal-title":"Nat Rev Clin Oncol"},{"key":"863_CR17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3389\/fendo.2018.00446","volume":"9","author":"G Biondani","year":"2018","unstructured":"Biondani G, Peyron J (2018) Metformin, an anti-diabetic drug to target leukemia. Front Endocrinol 9:446","journal-title":"Front Endocrinol"},{"issue":"7","key":"863_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3324\/haematol.2011.049981","volume":"97","author":"C Bono","year":"2012","unstructured":"Bono C, Karlin L, Harel S, Mouly E, Labaume S, Galicier L et al (2012) The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica 97(7):1101","journal-title":"Haematologica"},{"issue":"6","key":"863_CR19","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","volume":"78","author":"J Boshuizen","year":"2020","unstructured":"Boshuizen J, Peeper DS (2020) Rational cancer treatment combinations: an urgent clinical need. Mol Cell 78(6):1002\u20131018","journal-title":"Mol Cell"},{"issue":"6","key":"863_CR20","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ajh.25778","volume":"95","author":"E Br\u00e5nvall","year":"2020","unstructured":"Br\u00e5nvall E, Ekberg S, Eloranta S, W\u00e4sterlid T, Birmann BM, Smedby KE (2020) Statin use is associated with improved survival in multiple myeloma: a Swedish population-based study of 4315 patients. Am J Hematol 95(6):652\u2013661","journal-title":"Am J Hematol"},{"issue":"6","key":"863_CR21","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"863_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5644\/ama2006-124.242","volume":"48","author":"O Castaneda","year":"2019","unstructured":"Castaneda O, Baz R (2019) Multiple myeloma genomics\u2014a concise review. Acta Med Acad 48(1):57","journal-title":"Acta Med Acad"},{"key":"863_CR23","doi-asserted-by":"publisher","first-page":"801851","DOI":"10.3389\/fonc.2021.801851","volume":"11","author":"C Charalampous","year":"2022","unstructured":"Charalampous C, Kourelis T (2022) Minimal residual disease assessment in multiple myeloma patients: minimal disease with maximal implications. Front Oncol 11:801851","journal-title":"Front Oncol"},{"key":"863_CR24","unstructured":"Chemicalx: a deep learning library for drug pair scoring. Proceedings of the 28th ACM SIGKDD conference on knowledge discovery and data mining; 2022"},{"key":"863_CR25","doi-asserted-by":"crossref","unstructured":"Chen R, Chen B (2015) The role of dasatinib in the management of chronic myeloid leukemia. Drug Des Devel Ther:773\u2013779","DOI":"10.2147\/DDDT.S80207"},{"issue":"2","key":"863_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","volume":"32","author":"CS Chim","year":"2018","unstructured":"Chim CS, Kumar SK, Orlowski Ra, Cook G, Richardson PG, Gertz MA et al (2018) Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 32(2):252\u2013262","journal-title":"Leukemia"},{"issue":"3","key":"863_CR27","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41419-022-04651-w","volume":"13","author":"K Chroma","year":"2022","unstructured":"Chroma K, Skrott Z, Gursky J, Bacovsky J, Moudry P, Buchtova T et al (2022) A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment. Cell Death Dis 13(3):203","journal-title":"Cell Death Dis"},{"issue":"2","key":"863_CR28","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1046\/j.1365-2141.1998.00783.x","volume":"102","author":"RD Clutterbuck","year":"1998","unstructured":"Clutterbuck RD, Millar BC, Powles RL, Newman A, Catovsky D, Jarman M et al (1998) Inhibitory effect of simvastatin on the proliferation of human myeloid leukemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol 102(2):522\u2013527","journal-title":"Br J Haematol"},{"issue":"5","key":"863_CR29","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA et al (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327(5):464\u2013477","journal-title":"JAMA"},{"issue":"1","key":"863_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cpt.2480","volume":"111","author":"S Dagenais","year":"2022","unstructured":"Dagenais S, Russo L, Madsen A, Webster J, Becnel L (2022) Use of real-world evidence to drive drug development strategy and inform clinical trial design. Clin Pharmacol Ther 111(1):77\u201389","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"863_CR31","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-14-1088","volume":"21","author":"S Dalva-Aydemir","year":"2015","unstructured":"Dalva-Aydemir S, Bajpai R, Martinez M, Adekola KU, Kandela I, Wei C et al (2015) Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. Clin Cancer Res 21(5):1161\u20131171","journal-title":"Clin Cancer Res"},{"issue":"5","key":"863_CR32","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/bjh.13780","volume":"171","author":"DS Das","year":"2015","unstructured":"Das DS, Ray A, Song Y, Richardson P, Trikha M, Chauhan D et al (2015) Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IM iD\u00ae immunomodulatory drug pomalidomide. Br J Haematol 171(5):798\u2013812","journal-title":"Br J Haematol"},{"issue":"5","key":"863_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","volume":"11","author":"N Daver","year":"2021","unstructured":"Daver N, Venugopal S, Ravandi F (2021) FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J 11(5):104","journal-title":"Blood Cancer J"},{"issue":"35","key":"863_CR34","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M et al (2022) Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia. J Clin Oncol 40(35):4048\u20134059","journal-title":"J Clin Oncol"},{"issue":"1","key":"863_CR35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1182\/hematology.2023000508","volume":"2023","author":"LH de Assis","year":"2023","unstructured":"de Assis LH, Fassi DE, Hutchings M (2023) Bispecific antibody therapies. Hematology 2023(1):216\u2013222","journal-title":"Hematology"},{"key":"863_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20\u201333","journal-title":"J Health Econ"},{"issue":"10","key":"863_CR37","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng W, Oriol A et al (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18(10):1327\u20131337","journal-title":"Lancet Oncol"},{"issue":"2","key":"863_CR38","first-page":"147","volume":"133","author":"M Dimopoulos","year":"2019","unstructured":"Dimopoulos M, Siegel D, White DJ, Boccia R, Iskander KS, Yang Z et al (2019) Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. Blood, J Am Soc Hematol 133(2):147\u2013155","journal-title":"Blood, J Am Soc Hematol"},{"issue":"7","key":"863_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"key":"863_CR40","doi-asserted-by":"publisher","first-page":"174633","DOI":"10.1016\/j.ejphar.2021.174633","volume":"913","author":"L Ding","year":"2021","unstructured":"Ding L, Chen Q, Chen K, Jiang Y, Li G, Chen Q et al (2021) Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K\/AKT pathway attenuation and Myc downregulation. Eur J Pharmacol 913:174633","journal-title":"Eur J Pharmacol"},{"key":"863_CR41","doi-asserted-by":"publisher","first-page":"100713","DOI":"10.1016\/j.drup.2020.100713","volume":"52","author":"J Dini\u0107","year":"2020","unstructured":"Dini\u0107 J, Efferth T, Garc\u00eda-Sosa AT, Grahovac J, Padr\u00f3n JM, Pajeva I et al (2020) Repurposing old drugs to fight multidrug resistant cancers. Drug Resist Updat 52:100713","journal-title":"Drug Resist Updat"},{"issue":"5","key":"863_CR42","doi-asserted-by":"publisher","first-page":"e0231588","DOI":"10.1371\/journal.pone.0231588","volume":"15","author":"E Driehuis","year":"2020","unstructured":"Driehuis E, Oosterom N, Heil SG, Muller IB, Lin M, Kolders S et al (2020) Patient-derived oral mucosa organoids as an in vitro model for methotrexate induced toxicity in pediatric acute lymphoblastic leukemia. PLoS One 15(5):e0231588","journal-title":"PLoS One"},{"issue":"4","key":"863_CR43","first-page":"249","volume":"63","author":"GK Dy","year":"2013","unstructured":"Dy GK, Adjei AA (2013) Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 63(4):249\u2013279","journal-title":"CA Cancer J Clin"},{"issue":"35","key":"863_CR44","doi-asserted-by":"publisher","first-page":"56726","DOI":"10.18632\/oncotarget.11059","volume":"7","author":"D Dytfeld","year":"2016","unstructured":"Dytfeld D, Luczak M, Wrobel T, Usnarska-Zubkiewicz L, Brzezniakiewicz K, Jamroziak K et al (2016) Comparative proteomic profiling of refractory\/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. Oncotarget 7(35):56726","journal-title":"Oncotarget"},{"issue":"4","key":"863_CR45","first-page":"767","volume":"18","author":"T Efferth","year":"2001","unstructured":"Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR (2001) The anti-malarial artesunate is also active against cancer. Int J Oncol 18(4):767\u2013773","journal-title":"Int J Oncol"},{"issue":"18","key":"863_CR46","first-page":"1953","volume":"133","author":"T Facon","year":"2019","unstructured":"Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R et al (2019) Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood, J Am Soc Hematol 133(18):1953\u20131963","journal-title":"Blood, J Am Soc Hematol"},{"issue":"19","key":"863_CR47","first-page":"2702","volume":"129","author":"K Fischer","year":"2017","unstructured":"Fischer K, Al-Sawaf O, Fink A, Dixon M, Bahlo J, Warburton S et al (2017) Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood, J Am Soc Hematol 129(19):2702\u20132705","journal-title":"Blood, J Am Soc Hematol"},{"issue":"23","key":"863_CR48","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink A, Tandon M, Dixon M et al (2019) Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 380(23):2225\u20132236","journal-title":"N Engl J Med"},{"issue":"12","key":"863_CR49","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1016\/S1470-2045(20)30610-0","volume":"21","author":"M Frantzi","year":"2020","unstructured":"Frantzi M, Latosinska A, Mokou M, Mischak H, Vlahou A (2020) Drug repurposing in oncology. Lancet Oncol 21(12):e543","journal-title":"Lancet Oncol"},{"key":"863_CR50","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s11033-020-06073-3","volume":"48","author":"TC Fujita","year":"2021","unstructured":"Fujita TC, Sousa-Pereira N, Amarante MK, Watanabe MAE (2021) Acute lymphoid leukemia etiopathogenesis. Mol Biol Rep 48:817\u2013822","journal-title":"Mol Biol Rep"},{"issue":"22","key":"863_CR51","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.3390\/cancers16223884","volume":"16","author":"P Garg","year":"2024","unstructured":"Garg P, Singhal G, Kulkarni P, Horne D, Salgia R, Singhal SS (2024) Artificial intelligence\u2013driven computational approaches in the development of anticancer drugs. Cancers 16(22):3884","journal-title":"Cancers"},{"issue":"10","key":"863_CR52","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.3109\/10428194.2011.580478","volume":"52","author":"J Gera","year":"2011","unstructured":"Gera J, Lichtenstein A (2011) The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma. Leuk Lymphoma 52(10):1857\u20131866","journal-title":"Leuk Lymphoma"},{"key":"863_CR53","doi-asserted-by":"crossref","unstructured":"Gholizadeh E, Zangene E, Vadadokhau U, Ritz D, Miettinen JJ, Soliymani R et al Exploring mechanisms of action in combinatorial therapies through solubility alterations: advancing AML treatment. bioRxiv 2024:2024.11. 08.618644","DOI":"10.1101\/2024.11.08.618644"},{"issue":"1","key":"863_CR54","doi-asserted-by":"publisher","first-page":"22153","DOI":"10.1038\/s41598-020-78315-0","volume":"10","author":"N Gimenez","year":"2020","unstructured":"Gimenez N, Tripathi R, Gir\u00f3 A, Rosich L, L\u00f3pez-Guerra M, L\u00f3pez-Oreja I et al (2020) Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia. Sci Rep 10(1):22153","journal-title":"Sci Rep"},{"issue":"6","key":"863_CR55","doi-asserted-by":"publisher","first-page":"2202506","DOI":"10.1002\/adhm.202202506","volume":"12","author":"F G\u00f6k\u00e7e","year":"2023","unstructured":"G\u00f6k\u00e7e F, Kaestli A, Lohasz C, De Geus M, Kaltenbach H, Renggli K et al (2023) Microphysiological drug-testing platform for identifying responses to prodrug treatment in primary leukemia. Adv Healthc Mater 12(6):2202506","journal-title":"Adv Healthc Mater"},{"key":"863_CR56","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.gore.2016.11.007","volume":"19","author":"S Grover","year":"2017","unstructured":"Grover S, Xu M, Jhingran A, Mahantshetty U, Chuang L, Small W Jr et al (2017) Clinical trials in low and middle-income countries\u2014successes and challenges. Gynecol Oncol Rep 19:5\u20139","journal-title":"Gynecol Oncol Rep"},{"issue":"6","key":"863_CR57","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jmoldx.2014.07.002","volume":"16","author":"ML Gulley","year":"2014","unstructured":"Gulley ML, Morgan DR (2014) Molecular oncology testing in resource-limited settings. J Mol Diagn 16(6):601\u2013611","journal-title":"J Mol Diagn"},{"key":"863_CR58","doi-asserted-by":"publisher","first-page":"105060","DOI":"10.1016\/j.compbiomed.2021.105060","volume":"140","author":"JR Hamre III","year":"2022","unstructured":"Hamre JR III, Klimov DK, McCoy MD, Jafri MS (2022) Machine learning-based prediction of drug and ligand binding in BCL-2 variants through molecular dynamics. Comput Biol Med 140:105060","journal-title":"Comput Biol Med"},{"issue":"6","key":"863_CR59","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","volume":"115","author":"I Hanamura","year":"2022","unstructured":"Hanamura I (2022) Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol 115(6):762\u2013777","journal-title":"Int J Hematol"},{"key":"863_CR60","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3389\/fonc.2017.00273","volume":"7","author":"JJ Hernandez","year":"2017","unstructured":"Hernandez JJ, Pryszlak M, Smith L, Yanchus C, Kurji N, Shahani VM et al (2017) Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front Oncol 7:273","journal-title":"Front Oncol"},{"issue":"2","key":"863_CR61","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1089\/ten.tec.2016.0404","volume":"23","author":"M Houshmand","year":"2017","unstructured":"Houshmand M, Soleimani M, Atashi A, Saglio G, Abdollahi M, Nikougoftar Zarif M (2017) Mimicking the acute myeloid leukemia niche for molecular study and drug screening. Tissue Eng Part C Methods 23(2):72\u201385","journal-title":"Tissue Eng Part C Methods"},{"issue":"6","key":"863_CR62","first-page":"1819","volume":"29","author":"G Hu","year":"2021","unstructured":"Hu G, Dong K, Dong J, Wang Y, Gao W (2021) Effects of artesunate combined with arsenious acid on proliferation and apoptosis of multiple myeloma cells via PI3K\/AKT signaling pathway. Zhongguo Shi Yan Xue Ye Xue Za Zhi 29(6):1819\u20131824","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"863_CR63","doi-asserted-by":"crossref","unstructured":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. 18th international myeloma workshop; 2021","DOI":"10.1182\/blood-2020-139009"},{"issue":"6","key":"863_CR64","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/bloodadvances.2022008316","volume":"7","author":"GC Issa","year":"2023","unstructured":"Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM et al (2023) Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933\u2013942","journal-title":"Blood Adv"},{"issue":"2","key":"863_CR65","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/cancers12020265","volume":"12","author":"S Ito","year":"2020","unstructured":"Ito S (2020) Proteasome inhibitors for the treatment of multiple myeloma. Cancers 12(2):265","journal-title":"Cancers"},{"issue":"10","key":"863_CR66","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1182\/bloodadvances.2022008966","volume":"7","author":"DN Iyer","year":"2023","unstructured":"Iyer DN, Schimmer AD, Chang H (2023) Applying CRISPR-Cas9 screens to dissect hematological malignancies. Blood Adv 7(10):2252\u20132270","journal-title":"Blood Adv"},{"issue":"11","key":"863_CR67","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1038\/leu.2015.157","volume":"29","author":"S Jagannathan","year":"2015","unstructured":"Jagannathan S, Abdel-Malek M, Malek E, Vad N, Latif T, Anderson KC et al (2015) Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib. Leukemia 29(11):2184\u20132191","journal-title":"Leukemia"},{"issue":"4","key":"863_CR68","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.3390\/ijms24044235","volume":"24","author":"JR James","year":"2023","unstructured":"James JR, Curd J, Ashworth JC, Abuhantash M, Grundy M, Seedhouse CH et al (2023) Hydrogel-based pre-clinical evaluation of repurposed FDA-approved drugs for AML. Int J Mol Sci 24(4):4235","journal-title":"Int J Mol Sci"},{"issue":"3","key":"863_CR69","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","volume":"22","author":"H Jin","year":"2023","unstructured":"Jin H, Wang L, Bernards R (2023) Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov 22(3):213\u2013234","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"863_CR70","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1074\/mcp.RA117.000539","volume":"17","author":"HE Johnston","year":"2018","unstructured":"Johnston HE, Carter MJ, Larrayoz M, Clarke J, Garbis SD, Oscier D et al (2018) Proteomics profiling of CLL versus healthy B-cells identifies putative therapeutic targets and a subtype-independent signature of spliceosome dysregulation. Mol Cell Proteomics 17(4):776\u2013791","journal-title":"Mol Cell Proteomics"},{"key":"863_CR71","first-page":"35","volume-title":"Genomics-driven drug discovery through pharmacogenomics","author":"C Joshi","year":"2025","unstructured":"Joshi C, Makwana D (2025) Advanced high throughput screening platforms in drug discovery. In: Genomics-driven drug discovery through pharmacogenomics. IGI Global Scientific Publishing, Hershey, pp 35\u201374"},{"issue":"19","key":"863_CR72","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.2174\/1568026616666160216154441","volume":"16","author":"E Ju Yang","year":"2016","unstructured":"Ju Yang E, Wu C, Liu Y, Lv J, Sup Shim J (2016) Revisiting non-cancer drugs for cancer therapy. Curr Top Med Chem 16(19):2144\u20132155","journal-title":"Curr Top Med Chem"},{"issue":"13","key":"863_CR73","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1182\/blood-2005-07-2819","volume":"106","author":"A Kardosh","year":"2005","unstructured":"Kardosh A, Soriano N, Liu Y, Uddin J, Petasis NA, Hofman FM et al (2005) Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non\u2013COX-2 inhibitory analog of celecoxib. Blood 106(13):4330\u20134338","journal-title":"Blood"},{"issue":"1","key":"863_CR74","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1038\/s41598-024-55286-0","volume":"14","author":"R Kawakatsu","year":"2024","unstructured":"Kawakatsu R, Tadagaki K, Yamasaki K, Yoshida T (2024) Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate. Sci Rep 14(1):4975","journal-title":"Sci Rep"},{"issue":"6","key":"863_CR75","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/sj.onc.1209117","volume":"25","author":"UK Khanzada","year":"2006","unstructured":"Khanzada UK, Pardo OE, Meier C, Downward J, Seckl Ma, Arcaro A (2006) Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene 25(6):877\u2013887","journal-title":"Oncogene"},{"issue":"3","key":"863_CR76","first-page":"406","volume":"116","author":"J Kikuchi","year":"2010","unstructured":"Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K et al (2010) Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood, J Am Soc Hematol 116(3):406\u2013417","journal-title":"Blood, J Am Soc Hematol"},{"key":"863_CR77","doi-asserted-by":"publisher","first-page":"9","DOI":"10.12688\/f1000research.5827.2","volume":"4","author":"T Koltai","year":"2015","unstructured":"Koltai T (2015) Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity. F1000Research 4:9","journal-title":"F1000Research"},{"key":"863_CR78","doi-asserted-by":"crossref","unstructured":"Koomen DC, Guingab-Cagmat JD, Oliveira PS, Fang B, Liu M, Welsh EA et al (2019) Proteometabolomics of melphalan resistance in multiple myeloma. Metabolomics Methods Protoc:273\u2013296","DOI":"10.1007\/978-1-4939-9488-5_21"},{"issue":"11","key":"863_CR79","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1089\/omi.2019.0151","volume":"23","author":"M Koromina","year":"2019","unstructured":"Koromina M, Pandi M, Patrinos GP (2019) Rethinking drug repositioning and development with artificial intelligence, machine learning, and omics. Omics J Integr Biol 23(11):539\u2013548","journal-title":"Omics J Integr Biol"},{"issue":"3","key":"863_CR80","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1038\/bcj.2013.2","volume":"3","author":"M Kraus","year":"2013","unstructured":"Kraus M, Bader J, Overkleeft H, Driessen C (2013) Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J 3(3):e103","journal-title":"Blood Cancer J"},{"issue":"1","key":"863_CR81","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/hon.3076","volume":"41","author":"FA Lagunas-Rangel","year":"2023","unstructured":"Lagunas-Rangel FA (2023) DNA damage accumulation and repair defects in FLT3-ITD acute myeloid leukemia: implications for clonal evolution and disease progression. Hematol Oncol 41(1):26\u201338","journal-title":"Hematol Oncol"},{"key":"863_CR82","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/B978-0-443-15380-8.00003-5","volume-title":"Biosensors in precision medicine","author":"LY Lan","year":"2024","unstructured":"Lan LY, Kumar WM, Liu LS, Roberts AK, Chen S, Snyder M (2024) Biomarkers in precision medicine. In: Biosensors in precision medicine. Elsevier, Amsterdam, pp 35\u201357"},{"issue":"6","key":"863_CR83","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/jpm11060463","volume":"11","author":"M Lasica","year":"2021","unstructured":"Lasica M, Anderson MA (2021) Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med 11(6):463","journal-title":"J Pers Med"},{"key":"863_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12859-019-3013-0","volume":"20","author":"G Lee","year":"2019","unstructured":"Lee G, Park C, Ahn J (2019) Novel deep learning model for more accurate prediction of drug-drug interaction effects. BMC Bioinform 20:1\u20138","journal-title":"BMC Bioinform"},{"issue":"1","key":"863_CR85","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1182\/hematology.2023000433","volume":"2023","author":"H Lee","year":"2023","unstructured":"Lee H, Neri P, Bahlis NJ (2023) Current use of bispecific antibodies to treat multiple myeloma. Hematology 2023(1):332\u2013339","journal-title":"Hematology"},{"issue":"1","key":"863_CR86","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41467-022-29224-5","volume":"13","author":"IR Leo","year":"2022","unstructured":"Leo IR, Aswad L, Stahl M, Kunold E, Post F, Erkers T et al (2022) Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines. Nat Commun 13(1):1691","journal-title":"Nat Commun"},{"issue":"2","key":"863_CR87","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s10528-023-10473-y","volume":"62","author":"Y Li","year":"2024","unstructured":"Li Y, Kan X (2024) Cuproptosis-related genes MTF1 and LIPT1 as novel prognostic biomarker in acute myeloid leukemia. Biochem Genet 62(2):1136\u20131159","journal-title":"Biochem Genet"},{"issue":"1","key":"863_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1145\/3678168","volume":"34","author":"H Li","year":"2024","unstructured":"Li H, Rajbahadur GK, Bezemer C (2024) Studying the impact of tensorflow and pytorch bindings on machine learning software quality. ACM Trans Softw Eng Methodol 34(1):1\u201331","journal-title":"ACM Trans Softw Eng Methodol"},{"issue":"20","key":"863_CR89","doi-asserted-by":"publisher","first-page":"7103","DOI":"10.3390\/molecules27207103","volume":"27","author":"J Liao","year":"2022","unstructured":"Liao J, Wang Q, Wu F, Huang Z (2022) In silico methods for identification of potential active sites of therapeutic targets. Molecules 27(20):7103","journal-title":"Molecules"},{"issue":"17","key":"863_CR90","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.3390\/molecules29174280","volume":"29","author":"JJ Lica","year":"2024","unstructured":"Lica JJ, Pradhan B, Safi K, Jak\u00f3bkiewicz-Banecka J, Hellmann A (2024) Promising therapeutic strategies for hematologic malignancies: innovations and potential. Molecules 29(17):4280","journal-title":"Molecules"},{"issue":"9","key":"863_CR91","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D et al (2023) Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med 29(9):2286\u20132294","journal-title":"Nat Med"},{"key":"863_CR92","doi-asserted-by":"crossref","unstructured":"Luo M, Tan T, Trussart M, Poch A, Nguyen MT, Speed TP et al (2024) Venetoclax dose escalation rapidly activates a BAFF\/BCL-2 survival axis in chronic lymphocytic leukemia. Blood J:blood. 2024024341","DOI":"10.1182\/blood.2024024341"},{"issue":"11","key":"863_CR93","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/cancers10110429","volume":"10","author":"M Luppi","year":"2018","unstructured":"Luppi M, Fabbiano F, Visani G, Martinelli G, Venditti A (2018) Novel agents for acute myeloid leukemia. Cancers 10(11):429","journal-title":"Cancers"},{"key":"863_CR94","doi-asserted-by":"publisher","first-page":"1117988","DOI":"10.3389\/fped.2023.1117988","volume":"11","author":"W Lv","year":"2023","unstructured":"Lv W, Chen T, Wang S, Li C, Zhang B, Wang L et al (2023) Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia. Front Pediatr 11:1117988","journal-title":"Front Pediatr"},{"key":"863_CR95","doi-asserted-by":"crossref","unstructured":"Mahoney E, Maddocks K, Flynn J, Jones J, Cole SL, Zhang X et al (2013) Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies. Leuk Lymphoma 54(12):2685\u20132692.","DOI":"10.3109\/10428194.2013.781168"},{"key":"863_CR96","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3389\/fimmu.2017.00954","volume":"8","author":"A Mansour","year":"2017","unstructured":"Mansour A, Wakkach A, Blin-Wakkach C (2017) Emerging roles of osteoclasts in the modulation of bone microenvironment and immune suppression in multiple myeloma. Front Immunol 8:954","journal-title":"Front Immunol"},{"key":"863_CR97","doi-asserted-by":"publisher","DOI":"10.1039\/9781839169236","volume-title":"Microfluidics and lab-on-a-chip","author":"A Manz","year":"2020","unstructured":"Manz A, Simone G, O\u2019Connor JS, Neuzil P (2020) Microfluidics and lab-on-a-chip. Royal Society of Chemistry, Cambridge"},{"key":"863_CR98","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1182\/blood-2018-99-113025","volume":"132","author":"CR Marinac","year":"2018","unstructured":"Marinac CR, Colditz GA, Rosner B, Ghobrial IM, Birmann BM (2018) Aspirin use and survival in multiple myeloma patients. Blood 132:3250","journal-title":"Blood"},{"issue":"12","key":"863_CR99","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.3109\/10428194.2014.896005","volume":"55","author":"TM Mark","year":"2014","unstructured":"Mark TM, Bowman IA, Rossi AC, Shah M, Rodriguez M, Quinn R et al (2014) Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leuk Lymphoma 55(12):2842\u20132849","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"863_CR100","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/hematology.2021000229","volume":"2021","author":"M Mateos","year":"2021","unstructured":"Mateos M, Mart\u00ednez BP, Gonz\u00e1lez-Calle V (2021) High-risk multiple myeloma: how to treat at diagnosis and relapse? Hematology 2021(1):30\u201336","journal-title":"Hematology"},{"key":"863_CR101","doi-asserted-by":"crossref","unstructured":"Meg\u00edas-Vericat JE, Ballesta-L\u00f3pez O, Barragan E, Montesinos P (2019) IDH1-mutated relapsed or refractory AML: current challenges and future prospects. Blood Lymphat Cancer: Targets Ther:19\u201332","DOI":"10.2147\/BLCTT.S177913"},{"issue":"11","key":"863_CR102","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1007\/s00277-024-05667-2","volume":"103","author":"Z Meng","year":"2024","unstructured":"Meng Z, Zheng H, Liu Y, Guo X, Chu S, Zhou W et al (2024) Prognostic significance of CRLF2 in patients with acute lymphoblastic leukemia: a meta-analysis and systematic review. Ann Hematol 103(11):4413\u20134425","journal-title":"Ann Hematol"},{"issue":"5","key":"863_CR103","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/bloodadvances.2021004934","volume":"6","author":"JM Middeke","year":"2022","unstructured":"Middeke JM, Metzeler KH, R\u00f6llig C, Kr\u00e4mer M, Eckardt J, Stasik S et al (2022) Differential impact of IDH1\/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Adv 6(5):1394\u20131405","journal-title":"Blood Adv"},{"issue":"16","key":"863_CR104","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G et al (2022) Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med 386(16):1519\u20131531","journal-title":"N Engl J Med"},{"key":"863_CR105","doi-asserted-by":"crossref","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L et al (2024) Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 25(8):1003\u20131014.","DOI":"10.1016\/S1470-2045(24)00282-1"},{"issue":"21","key":"863_CR106","doi-asserted-by":"publisher","first-page":"15518","DOI":"10.3390\/ijms242115518","volume":"24","author":"AG Mushebenge","year":"2023","unstructured":"Mushebenge AG, Ugbaja SC, Mbatha NA, Khan RB, Kumalo HM (2023) Assessing the potential contribution of in silico studies in discovering drug candidates that interact with various SARS-CoV-2 receptors. Int J Mol Sci 24(21):15518","journal-title":"Int J Mol Sci"},{"issue":"2","key":"863_CR107","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-020-01069-1","volume":"35","author":"R Nair","year":"2021","unstructured":"Nair R, Salinas-Illarena A, Baldauf H (2021) New strategies to treat AML: novel insights into AML survival pathways and combination therapies. Leukemia 35(2):299\u2013311","journal-title":"Leukemia"},{"key":"863_CR108","first-page":"1","volume":"57","author":"DM Naylor","year":"2015","unstructured":"Naylor DM, Kauppi DM, Schonfeld JM (2015) Therapeutic drug repurposing, repositioning and rescue. Drug Discov 57:1\u201316","journal-title":"Drug Discov"},{"issue":"7607","key":"863_CR109","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"N Nosengo","year":"2016","unstructured":"Nosengo N (2016) Can you teach old drugs new tricks? Nature 534(7607):314\u2013316","journal-title":"Nature"},{"key":"863_CR110","unstructured":"Old drugs, new uses: drug repurposing in hematological malignancies. Seminars in cancer biology: Elsevier; 2021"},{"issue":"11","key":"863_CR111","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s43018-020-00124-1","volume":"1","author":"K Oshima","year":"2020","unstructured":"Oshima K, Zhao J, P\u00e9rez-Dur\u00e1n P, Brown JA, Pati\u00f1o-Galindo JA, Chu T et al (2020) Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. Nat Cancer 1(11):1113\u20131127","journal-title":"Nat Cancer"},{"key":"863_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2024.2396046","volume":"65","author":"A \u00d8stergaard","year":"2024","unstructured":"\u00d8stergaard A, Boer JM, van Leeuwen FN, Pieters R, Den Boer ML (2024) IKZF1 in acute lymphoblastic leukemia: the rise before the fall? Leuk Lymphoma 65:1\u201311","journal-title":"Leuk Lymphoma"},{"key":"863_CR113","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1007\/s00277-020-04158-4","volume":"99","author":"S Palmieri","year":"2020","unstructured":"Palmieri S, Rocco S, Vitagliano O, Catalano L, Cerchione C, Vincelli ID et al (2020) KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients. Ann Hematol 99:2903\u20132909","journal-title":"Ann Hematol"},{"key":"863_CR114","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3332\/ecancer.2014.485","volume":"8","author":"P Pantziarka","year":"2014","unstructured":"Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP (2014) Repurposing drugs in oncology (ReDO)\u2014mebendazole as an anti-cancer agent. ecancermedicalscience 8:443","journal-title":"ecancermedicalscience"},{"issue":"5","key":"863_CR115","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3892\/mco.2024.2776","volume":"21","author":"P Papalexis","year":"2024","unstructured":"Papalexis P, Georgakopoulou VE, Drossos PV, Thymara E, Nonni A, Lazaris AC et al (2024) Precision medicine in breast cancer. Mol Clin Oncol 21(5):78","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"863_CR116","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/bph.14081","volume":"175","author":"A Papapetropoulos","year":"2018","unstructured":"Papapetropoulos A, Szabo C (2018) Inventing new therapies without reinventing the wheel: the power of drug repurposing. Br J Pharmacol 175(2):165","journal-title":"Br J Pharmacol"},{"issue":"6","key":"863_CR117","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3390\/cancers13061235","volume":"13","author":"T Paradzik","year":"2021","unstructured":"Paradzik T, Bandini C, Mereu E, Labrador M, Taiana E, Amodio N et al (2021) The landscape of signaling pathways and proteasome inhibitors combinations in multiple myeloma. Cancers 13(6):1235","journal-title":"Cancers"},{"issue":"17","key":"863_CR118","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.3390\/cancers16172931","volume":"16","author":"DS Parekh","year":"2024","unstructured":"Parekh DS, Tiger YKR, Jamouss KT, Hassani J, Bou Zerdan M, Raza S (2024) Updates on therapeutic strategies in the treatment of relapsed\/refractory multiple myeloma. Cancers 16(17):2931","journal-title":"Cancers"},{"issue":"3","key":"863_CR119","doi-asserted-by":"publisher","first-page":"117","DOI":"10.12793\/tcp.2021.29.e18","volume":"29","author":"K Park","year":"2021","unstructured":"Park K (2021) The use of real-world data in drug repurposing. Transl Clin Pharmacol 29(3):117","journal-title":"Transl Clin Pharmacol"},{"issue":"3","key":"863_CR120","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR et al (2010) How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge. Nat Rev Drug Discov 9(3):203\u2013214","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"863_CR121","first-page":"38","volume":"103","author":"A Pelcovits","year":"2020","unstructured":"Pelcovits A, Niroula R (2020) Acute myeloid leukemia: a review. R I Med J 103(3):38\u201340","journal-title":"R I Med J"},{"issue":"18","key":"863_CR122","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S et al (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 381(18):1728\u20131740","journal-title":"N Engl J Med"},{"issue":"2","key":"863_CR123","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cancers12020407","volume":"12","author":"V Pinto","year":"2020","unstructured":"Pinto V, Bergantim R, Caires HR, Seca H, Guimar\u00e3es JE, Vasconcelos MH (2020) Multiple myeloma: available therapies and causes of drug resistance. Cancers 12(2):407","journal-title":"Cancers"},{"key":"863_CR124","doi-asserted-by":"publisher","first-page":"1460100","DOI":"10.3389\/fddsv.2024.1460100","volume":"4","author":"L Pinzi","year":"2024","unstructured":"Pinzi L, Bisi N, Rastelli G (2024) How drug repurposing can advance drug discovery: challenges and opportunities. Front Drug Discov 4:1460100","journal-title":"Front Drug Discov"},{"issue":"3","key":"863_CR125","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","volume":"12","author":"D Plana","year":"2022","unstructured":"Plana D, Palmer AC, Sorger PK (2022) Independent drug action in combination therapy: implications for precision oncology. Cancer Discov 12(3):606\u2013624","journal-title":"Cancer Discov"},{"issue":"24","key":"863_CR126","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","volume":"3","author":"DA Pollyea","year":"2019","unstructured":"Pollyea DA, Amaya M, Strati P, Konopleva MY (2019) Venetoclax for AML: changing the treatment paradigm. Blood Adv 3(24):4326\u20134335","journal-title":"Blood Adv"},{"issue":"3","key":"863_CR127","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.3892\/ol.2017.6569","volume":"14","author":"R Pounds","year":"2017","unstructured":"Pounds R, Leonard S, Dawson C, Kehoe S (2017) Repurposing itraconazole for the treatment of cancer. Oncol Lett 14(3):2587\u20132597","journal-title":"Oncol Lett"},{"issue":"1","key":"863_CR128","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A et al (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18(1):41\u201358","journal-title":"Nat Rev Drug Discov"},{"issue":"13","key":"863_CR129","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1182\/blood-2004-06-2281","volume":"104","author":"N Raje","year":"2004","unstructured":"Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C et al (2004) Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104(13):4188\u20134193","journal-title":"Blood"},{"issue":"5","key":"863_CR130","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV (2020) Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol 95(5):548\u2013567","journal-title":"Am J Hematol"},{"issue":"8","key":"863_CR131","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(8):1086\u20131107","journal-title":"Am J Hematol"},{"issue":"3","key":"863_CR132","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","volume":"24","author":"SV Rajkumar","year":"2006","unstructured":"Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24(3):431\u2013436","journal-title":"J Clin Oncol"},{"issue":"16","key":"863_CR133","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.3390\/cancers13163978","volume":"13","author":"M Rausch","year":"2021","unstructured":"Rausch M, Rutz A, Allard P, Delucinge-Vivier C, Docquier M, Dormond O et al (2021) Drug repurposing to identify a synergistic high-order drug combination to treat sunitinib-resistant renal cell carcinoma. Cancers 13(16):3978","journal-title":"Cancers"},{"issue":"14","key":"863_CR134","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3390\/cells12141875","volume":"12","author":"JP Robinson","year":"2023","unstructured":"Robinson JP, Ostafe R, Iyengar SN, Rajwa B, Fischer R (2023) Flow cytometry: the next revolution. Cells 12(14):1875","journal-title":"Cells"},{"key":"863_CR135","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","volume":"15","author":"C Roder","year":"2015","unstructured":"Roder C, Thomson MJ (2015) Auranofin: repurposing an old drug for a golden new age. Drugs R 15:13\u201320","journal-title":"Drugs R"},{"issue":"3","key":"863_CR136","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3390\/ijms25031421","volume":"25","author":"C Rodr\u00edguez-Medina","year":"2024","unstructured":"Rodr\u00edguez-Medina C, Stuckey R, Bilbao-Sieyro C, G\u00f3mez-Casares MT (2024) Biomarkers of response to venetoclax therapy in acute myeloid leukemia. Int J Mol Sci 25(3):1421","journal-title":"Int J Mol Sci"},{"issue":"2","key":"863_CR137","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/10428194.2022.2136950","volume":"64","author":"AS Rosenberg","year":"2023","unstructured":"Rosenberg AS (2023) From mechanism to resistance\u2013changes in the use of dexamethasone in the treatment of multiple myeloma. Leuk Lymphoma 64(2):283\u2013291","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"863_CR138","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1080\/10428194.2020.1742900","volume":"61","author":"M Rosenzweig","year":"2020","unstructured":"Rosenzweig M, Palmer J, Tsai N, Synold T, Wu X, Tao S et al (2020) Repurposing leflunomide for relapsed\/refractory multiple myeloma: a phase 1 study. Leuk Lymphoma 61(7):1669\u20131677","journal-title":"Leuk Lymphoma"},{"key":"863_CR139","doi-asserted-by":"publisher","first-page":"104424","DOI":"10.1016\/j.critrevonc.2024.104424","volume":"201","author":"M Ruglioni","year":"2024","unstructured":"Ruglioni M, Crucitta S, Luculli GI, Tancredi G, Del Giudice ML, Mechell S et al (2024) Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated Acute Myeloid Leukemia (AML) to guide treatment strategy. Crit Rev Oncol Hematol 201:104424","journal-title":"Crit Rev Oncol Hematol"},{"issue":"18","key":"863_CR140","doi-asserted-by":"publisher","first-page":"E4304","DOI":"10.1073\/pnas.1803294115","volume":"115","author":"JY Ryu","year":"2018","unstructured":"Ryu JY, Kim HU, Lee SY (2018) Deep learning improves prediction of drug\u2013drug and drug\u2013food interactions. Proc Natl Acad Sci 115(18):E4304\u2013E4311","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"863_CR141","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/ph18010075","volume":"18","author":"H Sabit","year":"2025","unstructured":"Sabit H, Arneth B, Pawlik TM, Abdel-Ghany S, Ghazy A, Abdelazeem RM et al (2025) Leveraging single-cell multi-omics to decode tumor microenvironment diversity and therapeutic resistance. Pharmaceuticals 18(1):75","journal-title":"Pharmaceuticals"},{"issue":"1","key":"863_CR142","first-page":"71","volume":"9","author":"OM Salo-Ahen","year":"2020","unstructured":"Salo-Ahen OM, Alanko I, Bhadane R, Bonvin AM, Honorato RV, Hossain S et al (2020) Molecular dynamics simulations in drug discovery and pharmaceutical development. PRO 9(1):71","journal-title":"PRO"},{"key":"863_CR143","doi-asserted-by":"publisher","first-page":"1407698","DOI":"10.3389\/frhem.2024.1407698","volume":"3","author":"A Sharipol","year":"2024","unstructured":"Sharipol A, Frisch BJ (2024) Are we ready to integrate 3D culture systems in acute myeloid leukemia and bone marrow microenvironment research? Front Hematol 3:1407698","journal-title":"Front Hematol"},{"issue":"9","key":"863_CR144","doi-asserted-by":"publisher","first-page":"e75252","DOI":"10.1371\/journal.pone.0075252","volume":"8","author":"M Shen","year":"2013","unstructured":"Shen M, Zhang Y, Saba N, Austin CP, Wiestner A, Auld DS (2013) Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs. PLoS One 8(9):e75252","journal-title":"PLoS One"},{"issue":"12","key":"863_CR145","first-page":"1690","volume":"137","author":"M Simonin","year":"2021","unstructured":"Simonin M, Lhermitte L, Dourthe M, Lenglin\u00e9 E, Graux C, Grardel N et al (2021) IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL. Blood, J Am Soc Hematol 137(12):1690\u20131694","journal-title":"Blood, J Am Soc Hematol"},{"key":"863_CR146","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","volume":"124","author":"L Sleire","year":"2017","unstructured":"Sleire L, F\u00f8rde HE, Netland IA, Leiss L, Skeie BS, Enger P\u00d8 (2017) Drug repurposing in cancer. Pharmacol Res 124:74\u201391","journal-title":"Pharmacol Res"},{"issue":"6","key":"863_CR147","first-page":"916","volume":"11","author":"CE Staicu","year":"2021","unstructured":"Staicu CE, Jipa F, Axente E, Radu M, Radu BM, Sima F (2021) Lab-on-a-chip platforms as tools for drug screening in neuropathologies associated with blood\u2013brain barrier alterations. Biomol Ther 11(6):916","journal-title":"Biomol Ther"},{"issue":"7","key":"863_CR148","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J, Rotondo JC, Greve G, L\u00fcbbert M (2021) Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia 35(7):1873\u20131889","journal-title":"Leukemia"},{"issue":"5","key":"863_CR149","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD et al (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377(5):454\u2013464","journal-title":"N Engl J Med"},{"issue":"8","key":"863_CR150","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1182\/blood-2003-05-1543","volume":"103","author":"T Str\u00f6mberg","year":"2004","unstructured":"Str\u00f6mberg T, Dimberg A, Hammarberg A, Carlson K, Osterborg A, Nilsson K et al (2004) Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 103(8):3138\u20133147","journal-title":"Blood"},{"issue":"6","key":"863_CR151","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/ajh.25463","volume":"94","author":"RN Stuver","year":"2019","unstructured":"Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C et al (2019) Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. Am J Hematol 94(6):641\u2013649","journal-title":"Am J Hematol"},{"issue":"7","key":"863_CR152","first-page":"2049","volume":"109","author":"RE Szalat","year":"2024","unstructured":"Szalat RE, Anderson KC, Munshi NC (2024) Role of minimal residual disease assessment in multiple myeloma. Haematologica 109(7):2049","journal-title":"Haematologica"},{"key":"863_CR153","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3389\/fimmu.2018.01822","volume":"9","author":"Y Tai","year":"2018","unstructured":"Tai Y, Cho S, Anderson KC (2018) Osteoclast immunosuppressive effects in multiple myeloma: role of programmed cell death ligand 1. Front Immunol 9:1822","journal-title":"Front Immunol"},{"issue":"1","key":"863_CR154","doi-asserted-by":"publisher","first-page":"103422","DOI":"10.1016\/j.drudis.2022.103422","volume":"28","author":"GS Tan","year":"2023","unstructured":"Tan GS, Sloan EK, Lambert P, Kirkpatrick CM, Ilom\u00e4ki J (2023) Drug repurposing using real-world data. Drug Discov Today 28(1):103422","journal-title":"Drug Discov Today"},{"issue":"6","key":"863_CR155","first-page":"e572","volume":"5","author":"F Thol","year":"2021","unstructured":"Thol F, Heuser M (2021) Treatment for relapsed\/refractory acute myeloid leukemia. Hema 5(6):e572","journal-title":"Hema"},{"issue":"3","key":"863_CR156","doi-asserted-by":"publisher","first-page":"302","DOI":"10.2174\/1389450119666180803121737","volume":"20","author":"N To\u0142oczko-Iwaniuk","year":"2019","unstructured":"To\u0142oczko-Iwaniuk N, Dziemia\u0144czyk-Pakie\u0142a D, Nowaszewska BK, Celi\u0144ska-Janowicz K, Miltyk W (2019) Celecoxib in cancer therapy and prevention\u2013review. Curr Drug Targets 20(3):302\u2013315","journal-title":"Curr Drug Targets"},{"issue":"3","key":"863_CR157","doi-asserted-by":"publisher","first-page":"bbac075","DOI":"10.1093\/bib\/bbac075","volume":"23","author":"A Torkamannia","year":"2022","unstructured":"Torkamannia A, Omidi Y, Ferdousi R (2022) A review of machine learning approaches for drug synergy prediction in cancer. Brief Bioinform 23(3):bbac075","journal-title":"Brief Bioinform"},{"issue":"1","key":"863_CR158","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12910-021-00625-3","volume":"22","author":"EJ Tranv\u00e5g","year":"2021","unstructured":"Tranv\u00e5g EJ, Strand R, Ottersen T, Norheim OF (2021) Precision medicine and the principle of equal treatment: a conjoint analysis. BMC Med Ethics 22(1):55","journal-title":"BMC Med Ethics"},{"issue":"7","key":"863_CR159","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.3390\/ijms25073851","volume":"25","author":"S Ullas","year":"2024","unstructured":"Ullas S, Sinclair C (2024) Applications of flow cytometry in drug discovery and translational research. Int J Mol Sci 25(7):3851","journal-title":"Int J Mol Sci"},{"issue":"6","key":"863_CR160","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40258-023-00816-6","volume":"21","author":"KH van der Pol","year":"2023","unstructured":"van der Pol KH, Aljofan M, Blin O, Cornel JH, Rongen GA, Woestelandt A et al (2023) Drug repurposing of generic drugs: challenges and the potential role for government. Appl Health Econ Health Policy 21(6):831\u2013840","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"863_CR161","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3390\/cancers16050889","volume":"16","author":"SW Verbruggen","year":"2024","unstructured":"Verbruggen SW, Freeman CL, Freeman FE (2024) Utilizing 3D models to unravel the dynamics of myeloma plasma cells\u2019 escape from the bone marrow microenvironment. Cancers 16(5):889","journal-title":"Cancers"},{"issue":"6","key":"863_CR162","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","volume":"13","author":"A Waclawiczek","year":"2023","unstructured":"Waclawiczek A, Lepp\u00e4 A, Renders S, Stumpf K, Reyneri C, Betz B et al (2023) Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax. Cancer Discov 13(6):1408\u20131427","journal-title":"Cancer Discov"},{"key":"863_CR163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01162-7","volume":"14","author":"CT Wallington-Beddoe","year":"2021","unstructured":"Wallington-Beddoe CT, Mynott RL (2021) Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol 14:1\u201315","journal-title":"J Hematol Oncol"},{"issue":"3","key":"863_CR164","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/biomedicines10030638","volume":"10","author":"P Wander","year":"2022","unstructured":"Wander P, Arentsen-Peters ST, Vrenken KS, Pinhan\u04abos SM, Koopmans B, Dolman MEM et al (2022) High-throughput drug library screening in primary KMT2A-rearranged infant ALL cells favors the identification of drug candidates that activate P53 signaling. Biomedicines 10(3):638","journal-title":"Biomedicines"},{"issue":"W1","key":"863_CR165","doi-asserted-by":"publisher","first-page":"W356","DOI":"10.1093\/nar\/gkx374","volume":"45","author":"X Wang","year":"2017","unstructured":"Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X et al (2017) PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res 45(W1):W356\u2013W360","journal-title":"Nucleic Acids Res"},{"key":"863_CR166","doi-asserted-by":"publisher","first-page":"101144","DOI":"10.1016\/j.jpha.2024.101144","volume":"15","author":"B Wang","year":"2024","unstructured":"Wang B, Zhang T, Liu Q, Sutcharitchan C, Zhou Z, Zhang D et al (2024) Elucidating the role of artificial intelligence in drug development from the perspective of drug-target interactions. J Pharm Anal 15:101144","journal-title":"J Pharm Anal"},{"issue":"2","key":"863_CR167","doi-asserted-by":"publisher","first-page":"432","DOI":"10.37349\/etat.2024.00227","volume":"5","author":"P Winidmanokul","year":"2024","unstructured":"Winidmanokul P, Panya A, Okada S (2024) Tri-specific killer engager: unleashing multi-synergic power against cancer. Explor Target Anti-tumor Ther 5(2):432","journal-title":"Explor Target Anti-tumor Ther"},{"issue":"2","key":"863_CR168","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/cancers12020441","volume":"12","author":"AV Wojcicki","year":"2020","unstructured":"Wojcicki AV, Kadapakkam M, Frymoyer A, Lacayo N, Chae H, Sakamoto KM (2020) Repurposing drugs for acute myeloid leukemia: a worthy cause or a futile pursuit? Cancers 12(2):441","journal-title":"Cancers"},{"issue":"11","key":"863_CR169","doi-asserted-by":"publisher","first-page":"M110.005520","DOI":"10.1074\/mcp.M110.005520","volume":"10","author":"Y Xiang","year":"2011","unstructured":"Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ et al (2011) Monitoring a nuclear factor-\u03baB signature of drug resistance in multiple myeloma. Mol Cell Proteomics 10(11):M110.005520","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"863_CR170","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/cpt.1769","volume":"107","author":"H Xu","year":"2020","unstructured":"Xu H, Li J, Jiang X, Chen Q (2020) Electronic health records for drug repurposing: current status, challenges, and future directions. Clin Pharmacol Ther 107(4):712","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"863_CR171","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bjh.12909","volume":"166","author":"AJ Yee","year":"2014","unstructured":"Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA et al (2014) Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol 166(3):401\u2013409","journal-title":"Br J Haematol"},{"key":"863_CR172","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.canlet.2021.08.009","volume":"520","author":"H Yi","year":"2021","unstructured":"Yi H, Liang L, Wang H, Luo S, Hu L, Wang Y et al (2021) Albendazole inhibits NF-\u03baB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma. Cancer Lett 520:307\u2013320","journal-title":"Cancer Lett"},{"issue":"1","key":"863_CR173","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1038\/s41467-024-48616-3","volume":"15","author":"J Zhai","year":"2024","unstructured":"Zhai J, Liu Y, Ji W, Huang X, Wang P, Li Y et al (2024) Drug screening on digital microfluidics for cancer precision medicine. Nat Commun 15(1):4363","journal-title":"Nat Commun"},{"key":"863_CR174","first-page":"303","volume":"74","author":"B Zhang","year":"2014","unstructured":"Zhang B, Bolognia J, Marks P, Podoltsev N (2014) Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia. Cancer ChemotherPharmacol 74:303\u2013307","journal-title":"Cancer ChemotherPharmacol"},{"key":"863_CR175","doi-asserted-by":"publisher","first-page":"100905","DOI":"10.1016\/j.blre.2021.100905","volume":"52","author":"JC Zhao","year":"2022","unstructured":"Zhao JC, Agarwal S, Ahmad H, Amin K, Bewersdorf JP, Zeidan AM (2022) A review of FLT3 inhibitors in acute myeloid leukemia. Blood Rev 52:100905","journal-title":"Blood Rev"},{"issue":"11","key":"863_CR176","doi-asserted-by":"publisher","first-page":"e70046","DOI":"10.1002\/ctm2.70046","volume":"14","author":"A Zhu","year":"2024","unstructured":"Zhu A, Bai Y, Nan Y, Ju D (2024) Natural killer cell engagers: from bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy. Clin Transl Med 14(11):e70046","journal-title":"Clin Transl Med"},{"issue":"3","key":"863_CR177","doi-asserted-by":"publisher","first-page":"e0119857","DOI":"10.1371\/journal.pone.0119857","volume":"10","author":"KA Zub","year":"2015","unstructured":"Zub KA, Sousa MML, Sarno A, Sharma A, Demirovic A, Rao S et al (2015) Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells. PLoS One 10(3):e0119857","journal-title":"PLoS One"}],"container-title":["Advances in Experimental Medicine and Biology","Cell Biology and Translational Medicine, Volume 26"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2025_863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:06:18Z","timestamp":1781053578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/5584_2025_863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783032003805","9783032003812"],"references-count":177,"URL":"https:\/\/doi.org\/10.1007\/5584_2025_863","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"26 April 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}